Corporate Member Update: Merck-WELIREG™ (belzutifan)

Corporate Member Update: Merck-WELIREG™ (belzutifan)

WELIREG™ (belzutifan)
September, 2021

Merck Product Launch

Merck would like to inform you that WELIREG™ (belzutifan) 40-mg tablets has received FDA approval. WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

To read the full press release, please click here!

Become a NOS Member Today!

Platinum Corporate Members

Gold Corporate Members